[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620610":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":49,"centralContacts":53,"locations":61,"responsibleParty":145,"collaborators":147,"id":151,"slug":152,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":28,"eligibilityCriteria":157,"healthyVolunteers":153,"sex":158,"minAge":159,"maxAge":28,"enrollmentInfo":160,"targetDuration":28,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":64,"whyStopped":28,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"An intermediate dose (medium dose) of PTCY, tacrolimus, MMF, and the drug ruxolitinib","EXPERIMENTAL","will receive an intermediate (medium) dose of PTCY, tacrolimus, MMF,and ruxolitinib",[13,14,15,16],"Drug: Cyclophosphamide","Drug: Mycophenolate Mofetil","Drug: Ruxolitinib","Drug: Tacrolimus",{"label":18,"type":19,"description":20,"interventionNames":21},"A full dose of PTCY, tacrolimus, and MMF (the standard GVHD prevention approach)","ACTIVE_COMPARATOR","will receive a full dose of PTCY, tacrolimus, and MMF (the standard GVHD prevention approach)",[13,14,16],[23,29,32,38,42,46],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cyclophosphamide","An intermediate dose (medium dose) of Post-transplant Cyclophosphamide",[9],null,{"type":24,"name":25,"description":30,"armGroupLabels":31,"otherNames":28},"A full dose of Post-transplant Cyclophosphamide",[18],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Mycophenolate Mofetil","Day +5 to +35",[18,9],[37],"MMF",{"type":24,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Ruxolitinib","twice a day",[9],{"type":24,"name":43,"description":44,"armGroupLabels":45,"otherNames":28},"Tacrolimus","Day +5, taper per SoC",[18],{"type":24,"name":43,"description":47,"armGroupLabels":48,"otherNames":28},"Day +5, taper initiation within 2 weeks of starting Ruxolitinib",[9],[50],{"name":51,"affiliation":5,"role":52},"Doris Ponce, MD, MS","PRINCIPAL_INVESTIGATOR",[54,58],{"name":51,"role":55,"phone":56,"phoneExt":28,"email":57},"CONTACT","646-608-3739","BMTTrials@mskcc.org",{"name":59,"role":55,"phone":60,"phoneExt":28,"email":28},"Brian Shaffer, MD","646-608-3737",[62,79,90,101,113,124,134],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-74.54932,40.70621,{"lat":74,"lon":73},[77],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},"Doris Ponce, MD",{"facility":80,"status":64,"city":81,"state":66,"zip":82,"country":68,"countryCode":69,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":71,"coordinates":84},[85,86],-74.11709,40.39428,{"lat":86,"lon":85},[89],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":91,"status":64,"city":92,"state":66,"zip":93,"country":68,"countryCode":69,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","Montvale","07645",{"type":71,"coordinates":95},[96,97],-74.02292,41.04676,{"lat":97,"lon":96},[100],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":102,"status":64,"city":103,"state":104,"zip":105,"country":68,"countryCode":69,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":71,"coordinates":107},[108,109],-73.29289,40.84288,{"lat":109,"lon":108},[112],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":114,"status":64,"city":115,"state":104,"zip":116,"country":68,"countryCode":69,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":71,"coordinates":118},[119,120],-73.71263,40.96899,{"lat":120,"lon":119},[123],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":125,"status":64,"city":104,"state":104,"zip":126,"country":68,"countryCode":69,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","10065",{"type":71,"coordinates":128},[129,130],-74.00597,40.71427,{"lat":130,"lon":129},[133],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":135,"status":64,"city":136,"state":104,"zip":137,"country":68,"countryCode":69,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Memorial Sloan Kettering Nassau (Limited Protocol Activites)","Rockville Centre","11553",{"type":71,"coordinates":139},[140,141],-73.64124,40.65871,{"lat":141,"lon":140},[144],{"name":78,"role":55,"phone":56,"phoneExt":28,"email":28},{"type":146,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[148],{"name":149,"class":150},"Incyte Corporation","INDUSTRY","100620610","phase-2-a-study-of-ruxolitinib-for-preventing-graft-versus-host-disease-in-people-with-a-hematologic-malignancy-who-will-receive-a-stem-cell-transplant-100620610",false,"NCT07359859","A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY","Inclusion Criteria:\n\n* Patients ≥18- years-old at time of consent\n* Diagnosis: hematologic malignancy in morphologic remission (blasts \\\u003C5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed. Patients with lymphoma must have a complete or partial response\n* Donor: related or unrelated 7-8\u002F8 HLA-matched or related haploidentical\n* Karnofsky score ≥ 70%\n* Female subjects of childbearing potential (\\\u003C50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months.\n\n  °Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of the study drug. Effective birth control includes: \\*Intrauterine device (IUD) plus one barrier method \\*Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method \\*2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \\* A vasectomized partner.\n* For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug\n\nExclusion Criteria:\n\n* Recipient of CD34+ selected or engineered stem cell graft\n* Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin)\n* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ\n* Severely impaired renal function defined by serum creatinine \\> 2mg\u002FdL, renal dialysis requirement.\n* Use of investigational agent within 14 days pre-HCT\n* Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months\n* Uncontrolled psychiatric illness\n* Female patient who is pregnant or breastfeeding\n* Known allergy or sensitivity to ruxolitinib","ALL","18 Years",{"count":161,"type":162},40,"ESTIMATED","INTERVENTIONAL",[165],"PHASE2","The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).",[168],"Hematologic Malignancies",[170,171],"graft-versus-host disease (GVHD)","allogeneic hematopoietic stem cell transplant (allo-HCT)","2026-05-26",{"date":174,"type":175},"2026-05-27","ACTUAL",{"date":177,"type":175},"2026-01-20",{"date":179,"type":162},"2029-01",{"name":5,"class":6},7]